Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification

Public Health Reviews

Volumn 28, Issue 1-4, 2000, Pages 117-145

  Selhub, Jacob ^a   Jacques, Paul F ^a   Bostom, Andrew G ^b   Wilson, Peter W F ^b   Rosenberg, Irwin H ^a  

^a TUFTS UNIVERSITY   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

Author keywords

Carotid stenosis; Epidemiology; Folate fortification; Folic acid; Homocysteine; Pyridoxal phosphate; Vitamin B12; Vitamin B6

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; VITAMIN;

ADULT; AGED; CAROTID ARTERY OBSTRUCTION; CONFERENCE PAPER; DIET SUPPLEMENTATION; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; CAROTID STENOSIS; COHORT STUDIES; FEMALE; FOLIC ACID; FOOD, FORTIFIED; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; ODDS RATIO; RISK; UNITED STATES; VITAMIN B COMPLEX;

EID: 0034445732     PISSN: 03010422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (52)

1. McCully KS. Vascular pathology of homocysteinemia: implications for pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-128.
2. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-1082.
3. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62.
4. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.
5. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
6. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337: 230-236.
7. Bostom A., Silbershatz H, Jacques P, Selhub J, D'Agostino R, Wolf P, Rosenberg IH, Wilson P. Non-fasting plasma total homocysteine levels and all-cause cardiovascular disease mortality in elderly Framingham men and women Arch Intern Med 1999; 159: 1077-1080.
8. Steegers-Theunissen RP, Boers GH, Blom HJ, Nijhuis JG, Thomas CM, Borm GF, Eskes TK. Neural tube defects and elevated homocysteine levels in amniotic fluid. Am J Obstet Gynecol 1995; 172:1436-1441.
9. 12 are independent risk factors for neural tube defects. Q J Med 1993; 86: 703-708.
10. Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci USA 1996; 93: 15227-32.
11. Selhub J, Bagley LC, Miller J, Rosenberg IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 2000; 71 (suppl): 614S-620S.
12. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999; 19: 217-46.
13. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-2698.
14. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Plasma homocysteine and extracranial carotid artery stenosis in the Framingham Heart Study. N Engl J Med 1995; 332: 286-291.
15. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999; 340: 1449-1454.
16. Dawber TR, Moore FE, Mann GV. Coronary heart disease in the Framingham Study. Am J Public Health 1957; 47(suppl): 4-24.
17. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study. Design and preliminary data. Prev Med 1975; 4: 518-525.
18. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Fed Regist 1996; 61: 8781-8797.
19. Centers for Disease Control. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR 1992; 41(No. RR-14): 1-7.
20. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131-137.
21. Czeizel AE. Prevention of congenital abnormalities by periconceptional multivitamin supplementation. Br Med J 1993; 306: 1645-1648.
22. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J 1981; 282: 1509-1511.
23. Vergel RG, Sanchez LR, Heredero BL, Rodriguez PL, Martinez AJ. Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. Prenat Diagn 1990; 10: 149-152.
24. Smithells RW, Nevin NC, Seller MJ, et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1983; 1: 1027-1031.
25. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993; 269: 1257-1261.
26. Mulinare J, Cordero JF, Erickson JD, Berry RJ. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988; 260: 3141-3145.
27. Milunsky A, Jick H, Jick SS, Bruell CL, MacLaughlin DS, Rothman KJ, Willett W. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1989; 262; 2847-2852.
28. Bower C, Stanley FJ. Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in Western Australia. Med J Aust 1989; 150: 613-619.
29. Oakley GP, Jr. Eat right and take a multivitamin. N Engl J Med 1998; 338: 1060-1061.
30. Willett WC, Sampson LS, Stampfer MJ, et al. Reproducibility and validity of a semiquantitative food frequency questionaire. Am J Epidemiol 1985; 122: 51-65.
31. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881.
32. Joosten E, van den Berg A, Riezler R, et al. Metabolic evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am J Clin Nutr 1993; 58: 468-476.
33. Genest JJ, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990; 16: 1114-1119.
34. Brattstrom LE, Israelsson B, Jeppsson J-O, Hultberg BL. Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988; 48: 215-221.
35. Brattstrom L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: effects of pyridoxine and folic acid treatment. Atherosclerosis 1990; 81: 51-60.
36. Dudman NPB, Wilcken DEL, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease: its occurrence, cofactor therapy, and enzymology. Arterioscler Thromb 1993; 13: 1253-1260.
37. Glueck CJ, Shaw P, Lang JE, Tracy T, Sieve-Smith L, Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995; 132-136.
38. Franken DG, Boers GHJ, Blom HJ, Trijbels JMF. Effect of various regimens of vitamin B-6 and folic acid on mild hyperhomocysteinemia in vascular patients. J Inherit Metab Dis 1994; 17: 159-162.
39. Lindgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattstrom L. Plasma homocysteine in acute myocardial infarction: homo-cysteine-lowering effect of folic acid. J Intern Med 1995; 237: 381-388.
40. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993; 57 :47-53.
41. Ubbink JB, Vermaak WJH, van der Merwe A, Beckeŗ PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994; 124: 1927-1933.
42. 2]folic acid with three levels of folate intake. FASEB J 1998;12: A511.
43. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009-1015.
44. Schorah CJ, Devitt H, Lucock M, Dowell AC. The responsiveness of plasma homocysteine to small increases in dietary folic acid: a primary care study. Eur J Clin Nutr 1988; 52: 407-411.
45. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism 1988; 37: 697-701.
46. Arnesen E, Refsum H, Bonna KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704-709.
47. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-1398.
48. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. JAMA 1997; 227:1775-1781.
49. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236.
50. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279: 359-364.
51. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 1996; 143: 845-859.
52. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996; 275: 1893-1896.